Low back pain is the number-1 contributor to global health burden in terms of years lived with disability^[@bib1]^. Chronic low back pain is the most common specific reason for prescribed opioid use^[@bib2]^ and has contributed to marked increases in opioid abuse^[@bib3]^. Finding effective solutions for chronic low back pain is a critical agenda item for health-care professionals worldwide.

Pain from the sacroiliac joint has long been recognized as a potential source of chronic low back pain, playing a role in 15% to 30% of patients with chronic low back pain^[@bib4]-[@bib6]^. Also, the sacroiliac joint is implicated in up to 40% of patients with new-onset low back pain after lumbar arthrodesis^[@bib7]^.

The effectiveness of nonsurgical treatments for chronic sacroiliac joint pain remains unclear. Periarticular radiofrequency ablation and periarticular corticosteroid injections are supported only by short-term evidence; to our knowledge, no long-term, high-quality evidence supports these treatments' effectiveness. Open surgical arthrodesis of the sacroiliac joint can be achieved through multiple approaches^[@bib8]^. With the advent of minimally invasive approaches, open arthrodesis of the sacroiliac joint has decreased in usage. The most studied minimally invasive sacroiliac joint arthrodesis device, triangular titanium implants, has evidence support from randomized trials^[@bib9],[@bib10]^, a multicenter single-arm trial^[@bib11]^, prospective case series^[@bib12]-[@bib15]^, and comparative case series^[@bib16]-[@bib18]^. We conducted a randomized trial of minimally invasive sacroiliac joint arthrodesis compared with conservative management, previously reporting short-term outcomes^[@bib10]^. Herein, we report 2-year results.

Materials and Methods
=====================

iMIA (iFuse Implant System Minimally Invasive Arthrodesis; SI-BONE) is a prospective, open-label, multicenter randomized controlled trial conducted at 9 European centers. Local ethics committees approved the protocol prior to study initiation. The trial was registered at ClinicalTrials.gov (NCT01741025). One-year results for iMIA were published previously^[@bib19]^. Details on the study design are presented in the [Appendix](#app1){ref-type="sec"}. In brief, subjects with clinically relevant pain originating from the sacroiliac joint were randomized to either conservative management or sacroiliac joint arthrodesis (Fig. [1](#fig1){ref-type="fig"}). Subjects had scheduled follow-up visits to 24 months after randomization. Assessments, described previously, included changes in low back pain (visual analog scale \[VAS\] for pain), leg pain, active straight leg raise for the affected side^[@bib20]^, Oswestry Disability Index (ODI)^[@bib21]^, EuroQoL EQ-5D^[@bib22]^, and Zung Depression Scale^[@bib23]^. In the sacroiliac joint arthrodesis cohort, computed tomographic (CT) scans were conducted immediately postoperatively and at 12 months.

![Patient flow. SIJA = sacroiliac joint arthrodesis, CM = conservative management, FU = follow-up, m = month, X-over = crossover, and LTFU = lost to FU.](jbjsam-101-400-g001.00022f1){#fig1}

Statistical Analysis
--------------------

The minimum sample size was 40 subjects in each group, providing a power of 80% to identify a difference of 20 VAS points in sacroiliac joint pain with the assumption of a standard deviation of 35 points. Accounting for expected loss to follow-up, the trial's sample size was inflated to 50 per group. T tests and repeated-measures analysis of variance were used to compare continuous variables. Ordinal end points were analyzed using the Wilcoxon test, logistic or proportional-odds logistic regression, or the McNemar test for paired observations. Poisson regression was used to compare the number of adverse events per subject across groups. The primary end point used an as-available data analysis approach without missing data imputation. The impact of crossover from conservative management to sacroiliac joint arthrodesis was investigated using a last-observation-carried-forward approach, substituting the last observation prior to crossover for subsequent values. Repeated-measures analysis of variance was used to compare all post-treatment change scores across the following subgroups: age, pain duration, relation to pregnancy, sex, body mass index (BMI), prior lumbar arthrodesis, use of opioids, and smoking. All statistical analyses were performed using R (The R Foundation)^[@bib24]^. All study data were 100% source-verified.

Results
=======

Between June 6, 2013, and May 15, 2015, 109 qualified subjects were enrolled; of these, 6 (4 assigned to conservative management and 2 assigned to sacroiliac joint arthrodesis) withdrew before any intervention, leaving 103 participating subjects (Fig. [1](#fig1){ref-type="fig"}). Baseline characteristics are displayed in Table I. The mean baseline low back pain scores were 77.7 points in the sacroiliac joint arthrodesis group and 73.0 points in the conservative management group (p = 0.06).

###### 

Baseline Characteristics of Enrolled and Randomized Subjects

                                                                         Conservative Management (N = 51)   Sacroiliac Joint Arthrodesis (N = 52)   P Value[\*](#tblfn1){ref-type="table-fn"}
  ---------------------------------------------------------------------- ---------------------------------- --------------------------------------- -------------------------------------------
  Age[†](#tblfn2){ref-type="table-fn"} *(yr)*                            46.7 (23 to 69)                    49.4 (27 to 70)                         0.210
  Female sex[‡](#tblfn3){ref-type="table-fn"}                            37 (72.5%)                         38 (73.1%)                              0.999
  Pain duration[†](#tblfn2){ref-type="table-fn"} *(yr)*                  4.5 (0.45 to 23)                   4.9 (0.58 to 44)                        0.777
  BMI[†](#tblfn2){ref-type="table-fn"} *(kg/m*^*2*^*)*                   27.6 (16 to 44)                    26.5 (18 to 42)                         0.355
  Smoking[‡](#tblfn3){ref-type="table-fn"}                                                                                                          0.044
   Current                                                               16 (31.4%)                         23 (44.2%)                              
   Former                                                                8 (15.7%)                          14 (26.9%)                              
   Never                                                                 27 (52.9%)                         15 (28.8%)                              
  Pain syndrome[‡](#tblfn3){ref-type="table-fn"}                                                                                                    
   Pain began in peripartum period                                       3 (5.9%)                           6 (11.5%)                               0.488
   Radiates down leg                                                     40 (78.4%)                         42 (80.8%)                              0.811
   Pain in groin                                                         36 (70.6%)                         31 (59.6%)                              0.303
   Pain sitting                                                          38 (74.5%)                         42 (80.8%)                              0.486
   Pain rising                                                           40 (78.4%)                         48 (92.3%)                              0.055
   Pain walking                                                          42 (82.4%)                         43 (82.7%)                              0.999
   Pain climbing stairs                                                  41 (80.4%)                         41 (78.8%)                              0.999
   Pain descending stairs                                                29 (56.9%)                         33 (63.5%)                              0.549
  Prior treatment[‡](#tblfn3){ref-type="table-fn"}                                                                                                  
   Prior physical therapy                                                27 (52.9%)                         32 (61.5%)                              0.429
   Prior prolotherapy                                                    0 (0%)                             0 (0%)                                  0.999
   Prior corticosteroid sacroiliac joint injections                      38 (74.5%)                         37 (71.2%)                              0.825
   Prior radiofrequency ablation[§](#tblfn4){ref-type="table-fn"}        6 (11.8%)                          11 (21.2%)                              0.289
  Work status[‡](#tblfn3){ref-type="table-fn"}                                                                                                      0.792
   Working normal hours                                                  3 (5.9%)                           5 (9.6%)                                
   Working with limitations                                              12 (23.5%)                         13 (25.0%)                              
   Not working due to lower back pain                                    27 (52.9%)                         23 (44.2%)                              
   Not working due to other reason                                       2 (3.9%)                           1 (1.9%)                                
   Retired                                                               7 (13.7%)                          10 (19.2%)                              
  Ambulatory status[‡](#tblfn3){ref-type="table-fn"}                                                                                                0.295
   Ambulatory without assistance                                         46 (90.2%)                         42 (80.8%)                              
   Ambulatory with assistance                                            3 (5.9%)                           8 (15.4%)                               
   Cannot walk                                                           2 (3.9%)                           2 (3.8%)                                
  History of prior lumbar arthrodesis[‡](#tblfn3){ref-type="table-fn"}   19 (37.3%)                         18 (34.6%)                              0.839

The Fisher test was used to determine p values for nominal variables, and the t test was used to determine p values for continuous variables.

The values are given as the mean, with the range in parentheses.

The values are given as the number of patients, with the percentage in parentheses.

This is radiofrequency ablation of the lateral branches of the sacral nerve root.

Of the subjects who underwent sacroiliac joint arthrodesis, 7 had bilateral pain and underwent staged bilateral sacroiliac joint arthrodesis, 11 had bilateral pain but underwent only unilateral sacroiliac joint arthrodesis, 6 with initial unilateral pain underwent bilateral sacroiliac joint arthrodesis, and the remainder underwent unilateral sacroiliac joint arthrodesis for unilateral pain. All but 1 case used 3 implants on the treated side (Table II); in the remaining subject, 4 implants were used on the treated side. The median hospital length of stay was 3 days (range, 1 to 28 days). Subjects assigned to conservative management underwent a mean of 25 physical therapy sessions over the first 6 months. Two subjects in the conservative management group underwent sacroiliac joint corticosteroid injections and 1 subject underwent sacroiliac joint corticosteroid injection and radiofrequency ablation as deviations from the investigational protocol.

###### 

Description of Operative Characteristics (Index Side Only) and Conservative Management

  Study Group                                                                   Value
  ----------------------------------------------------------------------------- ------------------
  Sacroiliac joint arthrodesis (n = 52)                                         
   Time from enrollment to surgery[\*](#tblfn5){ref-type="table-fn"} *(days)*   18 (1 to 82)
   No. of implants[†](#tblfn6){ref-type="table-fn"}                             
    3                                                                           51 (98.1%)
    4                                                                           1 (1.9%)
   Procedure duration[\*](#tblfn5){ref-type="table-fn"} *(min)*                 54 (19 to 107)
   Fluoroscopy time[\*](#tblfn5){ref-type="table-fn"} *(min)*                   2.1 (1.0 to 4.0)
   Hospital length of stay[\*](#tblfn5){ref-type="table-fn"} *(days)*           3 (1 to 28)
  Conservative management (n = 51)                                              
   Physical therapy sessions[†](#tblfn6){ref-type="table-fn"}                   
    1                                                                           1 (2.0%)
    2 to 4                                                                      2 (3.9%)
    5 to 10                                                                     1 (2.0%)
    11 to 15                                                                    9 (17.6%)
    \>15                                                                        38 (74.5%)
   Cognitive behavioral therapy sessions[†](#tblfn6){ref-type="table-fn"}       
    0                                                                           27 (52.9%)
    1                                                                           1 (2.0%)
    2 to 5                                                                      7 (13.7%)
    6 to 10                                                                     10 (19.6%)
    11 to 15                                                                    3 (5.9%)
    \>15                                                                        3 (5.9%)

The values are given as the median, with the range in parentheses.

The values are given as the number of patients, with the percentage in parentheses.

Low back pain improvement at 6 months was significantly larger in the sacroiliac joint arthrodesis group (43.3 points) compared with conservative management (5.7 points), a difference of 38 points (p \< 0.0001) (Fig. [2](#fig2){ref-type="fig"}). Improvement in low back pain after sacroiliac joint arthrodesis persisted at 24 months; the mean improvement was 45.3 points (95% confidence interval \[CI\], 37 to 54 points), 34 points higher than the conservative management group (p \< 0.0001). Improvements in leg pain paralleled those seen in low back pain, with minimal improvements in the conservative management group (by 1.4 points at 6 months and 7.7 points at 24 months) and large improvements (by 30 points at 6 months and 32 points at 24 months) in the sacroiliac joint arthrodesis group. In the conservative management group, the mean ODI improved minimally at 6 months (by 5.6 points) and 24 months (by 8 points); in contrast, the mean ODI improved rapidly in the sacroiliac joint arthrodesis group by 26 points (95% CI, 21 to 32 points) at 24 months. At 6 months, 79% (41 of 52) of subjects in the sacroiliac joint arthrodesis group had an improvement in low back pain by at least 20 VAS points compared with 22% (11 of 49) of subjects in the conservative management group. Twenty-four months after sacroiliac joint arthrodesis, 79% (37 of 47) had at least a 20-point improvement compared with 24% (11 of 46) in the conservative management group. Threshold 24-month improvements for the ODI occurred in 64% (30 of 47) in the sacroiliac joint arthrodesis group compared with 24% (11 of 46) in the conservative management group. Similar patterns were observed for the EQ-5D time trade-off, with large changes in the sacroiliac joint arthrodesis group at 6 months (0.37 point) and 24 months (0.39 point) and smaller changes in the conservative management group at 6 months (0.09 point) and 24 months (0.15 point). The mean Zung Depression Scale score showed no improvement in the conservative management group and a 5.3-point improvement in the sacroiliac joint arthrodesis group at 6 months, and this difference persisted at 24 months. All across-group comparisons reported here had p values of \<0.001. Subgroup analysis showed the following in the sacroiliac joint arthrodesis group at 6 months. Current smokers had a somewhat smaller decrease in VAS low back pain (38 points) compared with former smokers (52 points) and those who had never smoked (43 points); current smokers also had a somewhat smaller decrease in the ODI (21 points) compared with former smokers (29 points) and those who had never smoked (30 points). Baseline opioid users also had somewhat smaller ODI responses (22 points) compared with non-users (28 points) but similar VAS low back pain reduction. The reduction in VAS low back pain was larger in patients with higher baseline back pain scores; similarly, ODI improvements were larger in those with higher baseline scores.

![Change in VAS low back (LB) pain, VAS leg pain, ODI, EQ-5D time trade-off (TTO), EQ-5D VAS, and Zung Depression Scale scores. Blue indicates the conservative management group, and green indicates the sacroiliac joint arthrodesis group. The last-observation-carried-forward method was used to estimate values after crossover. The values shown are the mean. The error bars indicate the 95% CI.](jbjsam-101-400-g002.00022f2){#fig2}

The active straight leg raise showed no significant improvement in the conservative management group but large improvements after sacroiliac joint arthrodesis (p \< 0.0001 compared with baseline and p \< 0.0001 compared with conservative management) (Fig. [3](#fig3){ref-type="fig"}). Superior improvement in the number of positive physical examination findings was also observed (p \< 0.0001). The proportion of subjects using opioids decreased in the sacroiliac joint arthrodesis group from 56% at baseline to 33% at 24 months (McNemar p = 0.009) but was constant in the conservative management group (p = 1) (Fig. [4](#fig4){ref-type="fig"}).

![Change in functional test (active straight leg raise test) by treatment and time (left) and the number of positive physical examination signs (right). Blue indicates the conservative management group, and green indicates the sacroiliac joint arthrodesis group. The solid line indicates the right sacroiliac joint affected, and the dotted line indicates the left sacroiliac joint affected. The last-observation-carried-forward method was used to estimate values after crossover. The values shown are the mean. The error bars indicate the 95% CI.](jbjsam-101-400-g003.00022f3){#fig3}

![Proportion of subjects reporting opioid use in the past 2 weeks by treatment and study visit. Blue indicates the conservative management (CM) group, and green indicates the sacroiliac joint arthrodesis (SIJA) group.](jbjsam-101-400-g004.00022f4){#fig4}

Additional outcomes, such as walking distance, global comparison with baseline, and overall satisfaction, were superior after sacroiliac joint arthrodesis compared with conservative management (Figs. [5](#fig5){ref-type="fig"}-A, [5](#fig5){ref-type="fig"}-B, and [5](#fig5){ref-type="fig"}-C). In subjects in the sacroiliac joint arthrodesis group, work status improved significantly over time (p = 0.001).

###### 

**Figs. 5-A, 5-B, and 5-C** Bar graphs showing outcomes after conservative management (CM) and sacroiliac joint arthrodesis (SIJA). The last-observation-carried-forward method was used to estimate values after crossover.

![Change in walking distance and ambulatory status.](jbjsam-101-400-g005.00022f5a){#fig5a}

![Change in work status and comparison with baseline.](jbjsam-101-400-g006.00022f5b){#fig5b}

![Change in satisfaction and desirability of having a surgical procedure again by treatment and follow-up visit.](jbjsam-101-400-g007.00022f5c){#fig5c}

Crossover
---------

In the conservative management group, there was no early crossover to sacroiliac joint arthrodesis. After the 6-month visit, 21 subjects (43%) in the conservative management group crossed over to sacroiliac joint arthrodesis. Crossover subjects had similar baseline characteristics compared with subjects who did not cross over, with the exception of more leg pain and a higher proportion of opioid use (30% compared with 5%). Subjects who crossed over had higher 6-month low back pain, leg pain, and ODI scores compared with subjects who did not cross over. Additionally, subjects who crossed over at 6 months had almost no mean improvement in pain and the ODI by 6 months. In contrast, subjects who did not cross over had modest improvements in back pain and the ODI by 6 months. After crossover to sacroiliac joint arthrodesis, improvements in pain, disability, and quality of life were similar to those observed in subjects originally assigned to sacroiliac joint arthrodesis (Fig. [6](#fig6){ref-type="fig"}).

![Change in VAS low back (LB) pain, VAS leg pain, ODI, Zung Depression Scale, EQ-5D time trade-off (TTO), and EQ-5D VAS scores including subjects who crossed over from conservative management to sacroiliac joint arthrodesis. Green indicates the subjects initially assigned to sacroiliac joint arthrodesis, blue indicates subjects assigned to the conservative management group prior to crossover, and gray indicates conservative management subjects who crossed over to surgical treatment with the sacroiliac joint arthrodesis group after the 6-month visit. The values shown are the mean. The error bars indicate the 95% CI.](jbjsam-101-400-g008.00022f6){#fig6}

Adverse Events
--------------

During the first 6 months (200 days), 20 adverse events occurred in 16 subjects in the sacroiliac joint arthrodesis group and 17 adverse events occurred in 15 subjects in the conservative management group (Table III). The rate of events prior to 6 months was similar across groups: 0.33 in the sacroiliac joint arthrodesis group compared with 0.38 in the conservative management group (p = 0.6644).

###### 

Adverse Events by Relationship to Study Device, Severity, Treatment, and Timing

                           Conservative Management Event Severity[†](#tblfn8){ref-type="table-fn"}   Sacroiliac Joint Arthrodesis Event Severity[†](#tblfn8){ref-type="table-fn"}                 
  ------------ ----------- ------------------------------------------------------------------------- ------------------------------------------------------------------------------ ---- --- ---- ----
  No           ≤6 months   3                                                                         3                                                                              11   2   2    12
  \>6 months   2           10                                                                        15                                                                             4    7   23   
  Yes          ≤6 months   0                                                                         0                                                                              0    0   0    4
  \>6 months   1           1                                                                         1                                                                              0    0   0    
  All events   All         6                                                                         14                                                                             27   6   9    39

The time of 6 months corresponds to 200 days after assignment either to conservative management or sacroiliac joint arthrodesis.

The values are given as the number of adverse events.

By 24 months, 39 events occurred in the sacroiliac joint arthrodesis group that were rated as severe. Of these, only 4 were probably or definitely related to the study device or procedure: 2 cases of increased sacroiliac joint pain, 1 case of gluteal hematoma, and 1 case of implant-related nerve root impingement causing radicular pain that resolved after a revision surgical procedure. Severe events unrelated to the device or procedure included 14 events in the low back (e.g., disc herniation, lumbar facet pain), 3 events in the hip (e.g., trochanteric bursitis), 10 events in the pelvis (primarily sacroiliac joint or contralateral sacroiliac joint pain), and 8 events unrelated to the pelvis, spine, or hip. In the conservative management group, 27 severe adverse events were observed, of which only 1 was related to a study procedure. In this case, the subject had gluteal and leg pain after a crossover sacroiliac joint arthrodesis; CT showed implant loosening and the pain experienced by the subject responded to a repeat diagnostic sacroiliac joint block. A revision surgical procedure was performed with implant removal and intra-articular arthrodesis via a posteroinferior approach using screws.

Radiographic Analysis
---------------------

Forty-three of 52 subjects in the sacroiliac joint arthrodesis group had an evaluable 12-month CT scan, providing information on 35 right sides and 31 left sides with a total of 198 implants. Representative CT imaging is shown in Figure [7](#fig7){ref-type="fig"}. According to the independent radiologist reader, the following observations were made. There was no evidence of implant breakage or migration. Breaches (i.e., penetration of cortical margins) occurred in 17 (8.6%) of 198 implants, including 7 breaches into a sacral foramen. Breaches were more commonly observed in the caudal-most implant (11 cases).

![Imaging of typical configuration of implants. **Fig. 7-A** Inlet-view pelvic radiograph. **Fig. 7-B** A 12-month CT image from a different subject showing no radiolucencies around the first implant. **Fig. 7-C** A 12-month CT image from another subject showing radiolucency around the second implant in the sacrum.](jbjsam-101-400-g009.00022f7){#fig7}

Five implants (2.5%) showed radiolucency along a single side and 3 implants (1.5%) showed radiolucency along all 3 sides; none of these patients had clinical signs attributable to radiolucency. The majority of implants showed bone apposition to the implants on both the sacral and iliac sides of the sacroiliac joint (Fig. [8](#fig8){ref-type="fig"}). Intra-articular fusion with bridging of trabeculae from ilium to sacrum was not commonly observed. The mean implant engagement length (length from the distal end of the implant to the lateral sacral cortex) was approximately 25 to 28 mm for the first (cranial) implant and progressively decreased to 7 to 11 mm for the caudal-most implant (Table IV). There was no significant relationship between total implant engagement length and clinical responses.

![A 12-month CT image depicting bilateral implants with bone apposition along the entire length of the superior and inferior sides of both implants. Also, there is bone overgrowth at the outer iliac cortex (the left side is greater than the right side), suggesting complete implant integration into the ilium. However, there is little bone apposition along the implants within the joint.](jbjsam-101-400-g010.00022f8){#fig8}

###### 

Postoperative Engagement Length by Implant Number, View, and Side Measured in Subjects Undergoing Sacroiliac Joint Arthrodesis

  Implant Number       View (Side[\*](#tblfn9){ref-type="table-fn"})   No of Patients          Engagement Length[†](#tblfn10){ref-type="table-fn"} *(mm)*
  -------------------- ----------------------------------------------- ----------------------- ------------------------------------------------------------
  1 (superior)         Axial (anterior)                                64                      27.3 ± 5.5 (16 to 41)
  Axial (posterior)    64                                              23.5 ± 6.1 (5 to 35)    
  Coronal (superior)   63                                              27.9 ± 5.2 (15 to 44)   
  Coronal (inferior)   63                                              25 ± 5.5 (13 to 42)     
  2                    Axial (anterior)                                64                      19.2 ± 5.3 (9 to 36)
  Axial (posterior)    64                                              16 ± 5.2 (4 to 30)      
  Coronal (superior)   63                                              18.7 ± 5.1 (7 to 32)    
  Coronal (inferior)   63                                              16.3 ± 5 (7 to 28)      
  3                    Axial (anterior)                                63                      16.1 ± 5.7 (5 to 36)
  Axial (posterior)    59                                              13.2 ± 5.9 (0 to 26)    
  Coronal (superior)   62                                              15.6 ± 5.9 (1 to 33)    
  Coronal (inferior)   61                                              14.1 ± 5.6 (0 to 32)    
  4 (caudal)           Axial (anterior)                                1                       11
  Axial (posterior)    1                                               8                       
  Coronal (superior)   1                                               10                      
  Coronal (inferior)   1                                               7                       

The sides are determined as the anterior side of the implant on an axial view, the posterior side of the implant on an axial view, the superior side of the implant on a coronal view, and the inferior side of the implant on a coronal view.

The values for implants 1 to 3 are given as the mean and the standard deviation, with the range in parentheses; the values for implant 4 are given as the mean.

Discussion
==========

The results of this randomized controlled trial support sacroiliac joint arthrodesis with lateral transarticular placement of triangular titanium implants as a safe and effective treatment for chronic sacroiliac joint pain unresponsive to conservative management. Subjects undergoing sacroiliac joint arthrodesis experienced sustained improvements in multiple patient-reported parameters, including low back and leg pain, disability, and quality of life, as well as modest improvements in depression scores. Improvements were also seen in walking distance and work status. A unique feature of our study is the assessment of physical function, including the active straight leg raise test and repeat physical examination maneuvers that stress the sacroiliac joint, both of which showed improvements after sacroiliac joint arthrodesis but not after conservative management. In addition, similar improvements in key parameters occurred in conservative management subjects who crossed over to sacroiliac joint arthrodesis. In contrast, conservative management provided little, if any, net improvement in any of these parameters, including pain, disability, quality of life, depression scores, ability to perform the active straight leg raise test, or number of positive physical examination maneuvers. These findings provide evidence of the intermediate-term superiority of sacroiliac joint arthrodesis over continued conservative treatments in a patient population with debilitating chronic sacroiliac joint pain.

Although all study patients had undergone at least 6 months of conservative management prior to enrollment, with persistence of pain and disability, only a small portion of conservative management subjects experienced improvements in pain during the study. Of interest, patients in the conservative management group who experienced a clinically important improvement in low back pain by 6 months showed improvement starting as early as the first 3 months. This finding suggests that the conservative management treatment effect can be judged relatively quickly. Also, the proportion of subjects with opioid use decreased only after sacroiliac joint arthrodesis but not after conservative management. Because low back pain is a frequent trigger for long-term opioid use, our results support the view that the current discussion on the detrimental epidemiological impact of opioid use ought to include alternatives to conservative management that may help to decrease the demand for opioids.

Subgroup analysis showed that current smokers had somewhat smaller low back pain and ODI improvements after sacroiliac joint arthrodesis compared with nonsmokers. However, smokers still derived clinically important benefits from the procedure. These results are consistent with a pooled analysis of data from the current study and 2 U.S. studies^[@bib25]^.

Radiographic analysis, based on 12-month CT scans, showed no evidence of device migration or breakage. Breaches (i.e., the presence of some aspect of the implant outside of the sacral cortex on CT scan) were mostly not associated with clinical symptoms, with the exception of 1 subject with post-placement radicular pain that improved on surgical implant repositioning. Breach was more common in implants placed more caudally, confirming that caudal implant placement is more technically challenging. Symptomatic breaches typically manifest with immediate postoperative new neuropathic pain; in our study, late (12-month) CT scans did not show any breaches associated with new or recurrent symptoms. Radiolucencies occurred at a low frequency; no radiolucency seen by the independent radiologist was associated with new or recurrent symptoms. In 2 cases, radiolucencies seen by the investigator were associated with recurrent sacroiliac joint pain, and, in 1 case, a revision surgical procedure was performed to address apparent loosening of the implants. Implant engagement length into the sacrum was largest for the cranial-most implants and progressively decreased for the more caudal implants. Typically, the superior-most implant can be placed deeply into the sacral ala above the S1 neuroforamen. The sacral ala progressively narrows caudally and the presence of neuroforamina precludes deep implant placement for implants placed more caudally. Although increased total implant engagement length into the sacrum may improve sacroiliac joint stabilization, we were unable to demonstrate a significant relationship with clinical responses.

Binding of bone to implants within the sacrum and ilium was commonly seen; bridging bone, reflecting intra-articular fusion, which was not evaluated in our study, may take longer^[@bib9],[@bib26]^. However, in contrast to other joints that are surgically fused, the sacroiliac joint has very little inherent motion; our data substantiate that permanent stabilization with implants showing avid bone binding at 12 months results in excellent patient outcomes; whether maneuvers to accelerate fusion with obliteration of the sacroiliac joint improve patient outcomes is unclear.

No unanticipated adverse events occurred. The rate of revision surgical procedures in subjects undergoing sacroiliac joint arthrodesis (2 cases) was low and consistent with prior trials and analyses^[@bib9],[@bib11],[@bib15],[@bib27],[@bib28]^, which showed that the perforation of sacral nerve foramina rarely occurs after sacroiliac joint arthrodesis^[@bib27]^. In the literature, the revision rates after sacroiliac joint arthrodesis (3.4% at 4 years^[@bib27]^) are lower than after a lumbar spine surgical procedure (14% at 4 years^[@bib29]^).

Our findings are consistent with findings from a U.S. randomized trial^[@bib9]^, a prospective U.S. single-arm study^[@bib11]^, and several retrospective cohorts^[@bib12]-[@bib18]^. The improvements that we observed in low back pain were also similar to those observed in patients in the Swedish Spine Register of various spine surgical procedures^[@bib30]^.

Our study has multiple strengths, including its multicenter design according to a uniform clinical protocol with a control group receiving maximal conservative management, a standardized diagnostic algorithm, similar implant placement configurations across participating study centers, and 2-year follow-up. The primary limitation of our study was a lack of subject and outcome assessor blinding, which would have been challenging because implants are radiopaque and preventing subjects from seeing their radiographic studies would have been impossible. The large effect sizes seen strongly argue against a marked contribution from placebo effects. Although our trial followed nonsurgical European guidelines for the treatment of sacroiliac joint pain with intensive physical therapy provided, it is possible that more intensive conservative management might have provided somewhat better results. An additional limitation was the high crossover rate after 6 months. Finally, we note that our study utilized sacroiliac joint arthrodesis with a single system (triangular titanium implants); whether our results apply to other sacroiliac joint arthrodesis surgical approaches, systems, and devices is not known. Except for smoking status, baseline parameters were distributed evenly across treatment groups. Subjects assigned to sacroiliac joint arthrodesis were more likely to be smokers; if smoking reduces the rate of bone-healing, as is commonly accepted, the increased proportion of smokers in the sacroiliac joint arthrodesis group would have biased study results against sacroiliac joint arthrodesis. Post-randomization interventions or subject behaviors that could have impacted the study's results were not readily apparent; some subjects in the conservative management group received prolonged physical therapy, which theoretically could have increased its effect. The collection of information to support the calculation of health indices (e.g., Charlson Comorbidity Index^[@bib31]^) and further opioid history during a 6-month period prior to the study start could also have been helpful. An analysis of predictors of response in the conservative management group is also of interest; however, our sample size was too small to accomplish this goal.

In conclusion, minimally invasive sacroiliac joint arthrodesis with triangular titanium implants was safe and effective at 2 years for the treatment of chronic sacroiliac joint pain and provided lasting improvements compared with conservative management. Our findings suggest that minimally invasive sacroiliac joint arthrodesis may be a reasonable option for patients with sacroiliac joint pain not responsive to 6 months of conservative management.
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========

The details on the study design are available with the online version of this article as a data supplement at [jbjs.org](http://jbjs.org) (<http://links.lww.com/JBJS/F144>).
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